Reply from Authors re: Alexandre R. Zlotta, Robert K. Nam. to biopsy or not to biopsy - Thou shall think twice. Eur Urol 2012;61:1115-7: Considerations for prostate biopsy decisions

European Urology

Volumn 61, Issue 6, 2012, Pages 1117-1118

  Loeb, Stacy ^a   Van Den Heuvel, Suzanne ^b   Zhu, Xiaoye ^b   Bangma, Chris H ^b   Schroder, Fritz H ^b   Roobol, Monique J ^b  

^a NEW YORK UNIVERSITY   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER DIAGNOSIS; COMORBIDITY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; EUROPE; FOLLOW UP; HOSPITALIZATION; HUMAN; MALE; MEDICARE; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SCREENING TEST; TRANSRECTAL ULTRASONOGRAPHY;

EID: 84862816271     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.02.056     Document Type: Editorial

References (18)

1. S. Loeb, S. van den Heuvel, and X. Zhu Infectious complications and hospital admissions after prostate biopsy in a European randomized trial Eur Urol 61 2012 1110 1114
2. R.K. Nam, R. Saskin, and Y. Lee Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy J Urol 183 2010 963 968
3. S. Loeb, H.B. Carter, S.I. Berndt, W. Ricker, and E.M. Schaeffer Complications after prostate biopsy: data from SEER-Medicare J Urol 186 2011 1830 1834
4. The GLOBOCAN Project: GLOBOCAN estimated age-standardised incidence and mortality rates: Europe 2008 [fact sheet]. World Health Organization, International Agency for Research on Cancer Web site. http://globocan.iarc.fr/. Accessed February 14, 2011.
5. H.G. Welch, E.S. Fisher, D.J. Gottlieb, and M.J. Barry Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era J Natl Cancer Inst 99 2007 1395 1400 (Pubitemid 351767186)
6. A.R. Zlotta, and R.K. Nam To biopsy or not to biopsy - thou shall think twice Eur Urol 61 2012 1115 1117
7. J.J. Tosoian, B.J. Trock, and P. Landis Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185 2190
8. A.E. Ross, S. Loeb, and P. Landis Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program J Clin Oncol 28 2010 2810 2816
9. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534 538
10. Hoeks CMA, Schouten MG, Bomers JGR, et al. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. In press. doi:10.1016/j.eururo.2012.01.047.
11. So C, Kirby KA, Mehta K, et al. Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy. J Gen Intern Med. In press.
12. S. Loeb, E.J. Metter, D. Kan, K.A. Roehl, and W.J. Catalona Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer BJU Int 109 2012 508 513
13. AUA Response to 2011 U.S. Preventive Services Task Force Draft Recommendations on Prostate Cancer Testing. American Urological Association Web site. http://www.auanet.org/content/health-policy/government-relations-and- advocacy/in-the-news/aua-response-to-uspstf.cfm?acid=7333870728NE21Off717& WT.mc-id=NetNews7006. Accessed November 9, 2011.
14. M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
15. G. Trottier, M.J. Roobol, and N. Lawrentschuk Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort BJU Int 108 2011 E237 E244
16. van Vugt HA, Roobol MJ, Busstra M, et al. Compliance with biopsy recommendations of a prostate cancer risk calculator. BJU Int. In press.
17. M.J. Roobol, H.A. van Vugt, and S. Loeb Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators Eur Urol 61 2012 577 583
18. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732